2020
DOI: 10.15190/d.2020.5
|View full text |Cite
|
Sign up to set email alerts
|

COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
54
0

Year Published

2020
2020
2021
2021

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 48 publications
(55 citation statements)
references
References 64 publications
1
54
0
Order By: Relevance
“…The mainstay treatment for COVID-19 is supportive management, with oxygen and mechanical ventilation, if needed (159). Empiric antibiotics have been used to prevent superimposed infections (160). FDA gave emergency use authorization for Remdesivir on May 1st, 2020, and there are no other FDA-approved medications available for COVID-19 (159)(160)(161)(162).…”
Section: Treatmentmentioning
confidence: 99%
“…The mainstay treatment for COVID-19 is supportive management, with oxygen and mechanical ventilation, if needed (159). Empiric antibiotics have been used to prevent superimposed infections (160). FDA gave emergency use authorization for Remdesivir on May 1st, 2020, and there are no other FDA-approved medications available for COVID-19 (159)(160)(161)(162).…”
Section: Treatmentmentioning
confidence: 99%
“…Pneumonia is a common result of COVID-19 that is variably treated with a regimen of medications that are currently undergoing clinical studies ( Figure 5) [5]. Although there is no FDA-approved medicinal therapy or vaccine for the novel coronavirus, this case illustrates that various drugs can be repurposed to treat COVID-19 patients on a temporary basis before an official medication is approved [6]. Before arriving at the emergency department, the patient received azithromycin, which was later seen to be ineffective by itself.…”
Section: Discussionmentioning
confidence: 99%
“…This systematic review also identi ed the level of KAP on community-based intervention for preventing COVID-19 among participants in LMICs. Authors acknowledge other types of reviews (min-reviews, scoping, etc) conducted in area of COVID-19 (23,24). However, the current systematic review is unique in that its protocol is registered in a PROSPERO database, which is a register for systematic reviews.…”
Section: Discussionmentioning
confidence: 99%